Clinical Trials Browser

Rhabdomyosarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Gastrointestinal Stromal Tumors

Desmoid Tumors

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Brain Neoplasms, Glioblastoma, Gliosarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Sarcoma

Recurrent Uterine Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Sarcoma, Osteosarcoma

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Hemangiopericytoma, Malignant, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma

Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Osteosarcoma

Gastrointestinal Stromal Tumors

Hemangiosarcoma, Sarcoma

Clinical Trials

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Sorafenib and Dacarbazine in Soft Tissue Sarcoma

SERIO

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall

Sorafenib in Relapsed High Grade Osteosarcoma

Sorafenib for Imatinib/Sunitinib-failed GIST

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery

Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma